×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:POAI

Predictive Oncology Stock Forecast, Price & News

$0.41
0.00 (0.00%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.40
$0.43
50-Day Range
$0.27
$0.80
52-Week Range
$0.25
$1.47
Volume
165,479 shs
Average Volume
366,840 shs
Market Capitalization
$27.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Predictive Oncology MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Predictive Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$126,796 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.06) to ($0.01) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.08 out of 5 stars

Medical Sector

1086th out of 1,426 stocks

Surgical Appliances & Supplies Industry

20th out of 30 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

Predictive Oncology logo

About Predictive Oncology (NASDAQ:POAI) Stock

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

POAI Stock News Headlines

Predictive Oncology – Year-end Shareholder Update!
Predictive Oncology
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:POAI
Fax
N/A
Employees
22
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/06/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-19,660,000.00
Net Margins
-1,314.56%
Pretax Margin
-1,359.96%

Debt

Sales & Book Value

Annual Sales
$1.42 million
Book Value
$0.61 per share

Miscellaneous

Free Float
65,657,000
Market Cap
$27.33 million
Optionable
Not Optionable
Beta
1.40














Predictive Oncology Frequently Asked Questions

Should I buy or sell Predictive Oncology stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Predictive Oncology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Predictive Oncology stock.
View analyst ratings for Predictive Oncology
or view top-rated stocks.

How has Predictive Oncology's stock performed in 2022?

Predictive Oncology's stock was trading at $0.9519 at the start of the year. Since then, POAI shares have decreased by 56.6% and is now trading at $0.4131.
View the best growth stocks for 2022 here
.

When is Predictive Oncology's next earnings date?

Predictive Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Predictive Oncology
.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) issued its quarterly earnings data on Thursday, May, 12th. The medical instruments supplier reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The medical instruments supplier earned $0.32 million during the quarter, compared to analyst estimates of $1 million. Predictive Oncology had a negative net margin of 1,314.56% and a negative trailing twelve-month return on equity of 27.33%.
View Predictive Oncology's earnings history
.

Who are Predictive Oncology's key executives?

Predictive Oncology's management team includes the following people:
  • Mr. J. Melville Engle, Chairman & CEO (Age 72, Pay $508.57k)
  • Mr. Robert L. Myers, CFO & Sec. (Age 67, Pay $391.96k)
  • Mr. Richard L. Gabriel B.Sc, MBA, Sr. VP of R&D (Age 73, Pay $2.33k)
  • Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D., Sr. VP of Operations
  • Ms. Theresa Ferguson, Sr. Director of Marketing
  • Ms. Pamela Bush M.B.A., Ph.D., Sr. VP of Strategic Sales & Bus. Devel.
  • Dr. Arlette H. Uihlein FCAP, M.D., Sr. VP of Regulatory Affairs & Quality
  • Dr. Julia Kirshner Ph.D., Pres of zPredicta

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Blockchain (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE).

What is Predictive Oncology's stock symbol?

Predictive Oncology trades on the NASDAQ under the ticker symbol "POAI."

How do I buy shares of Predictive Oncology?

Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Predictive Oncology's stock price today?

One share of POAI stock can currently be purchased for approximately $0.41.

How much money does Predictive Oncology make?

Predictive Oncology (NASDAQ:POAI) has a market capitalization of $27.33 million and generates $1.42 million in revenue each year. The medical instruments supplier earns $-19,660,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Predictive Oncology have?

Predictive Oncology employs 22 workers across the globe.

How can I contact Predictive Oncology?

Predictive Oncology's mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The official website for Predictive Oncology is www.precisiontherapeutics.com. The medical instruments supplier can be reached via phone at (651) 389-4800 or via email at james@haydenir.com.

This page (NASDAQ:POAI) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.